AAAAAA

   
Results: 1-10 |
Results: 10
Prognostic value of TP53 gene mutation in adjuvant treated breast cancer patients
Authors: Powell, BL Bydder, S Grieu, F Gnanasampanthan, G Elsaleh, H Seshadri, R Berns, EMJJ Iacopetta, B
Citation: Bl. Powell et al., Prognostic value of TP53 gene mutation in adjuvant treated breast cancer patients, BREAST CANC, 69(1), 2001, pp. 65-68
Tamoxifen resistance in breast cancer - Elucidating mechanisms
Authors: Dorssers, LCJ van der Flier, S Brinkman, A van Agthoven, T Veldscholte, J Berns, EMJJ Klijn, JGM Beex, LVAM Foekens, JA
Citation: Lcj. Dorssers et al., Tamoxifen resistance in breast cancer - Elucidating mechanisms, DRUGS, 61(12), 2001, pp. 1721-1733
Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2
Authors: Schuyer, M van der Burg, MEL Henzen-Logmans, SC Fieret, JH Klijn, JGM Look, MP Foekens, JA Stoter, G Berns, EMJJ
Citation: M. Schuyer et al., Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2, BR J CANC, 85(9), 2001, pp. 1359-1367
Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features
Authors: Berns, EMJJ van Staveren, IL Verhoog, L van de Ouweland, AMW Meijer-van Gelder, M Meijers-Heijboer, H Portengen, H Foekens, JA Dorssers, LCJ Klijn, JGM
Citation: Emjj. Berns et al., Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features, BR J CANC, 85(4), 2001, pp. 538-545
Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients
Authors: Verhoog, LC Berns, EMJJ Brekelmans, CTM Seynaeve, C Meijers-Heijboer, EJ Klijn, JGM
Citation: Lc. Verhoog et al., Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients, J CL ONCOL, 18(21), 2000, pp. 119S-124S
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer
Authors: Berns, EMJJ Foekens, JA Vossen, R Look, MP Devilee, P Henzen-Logmans, SC van Staveren, IL van Putten, WLJ Inganas, M Meijer-van Gelder, ME Cornelisse, C Claassen, CJC Portengen, H Bakker, B Klijn, JGM
Citation: Emjj. Berns et al., Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer, CANCER RES, 60(8), 2000, pp. 2155-2162
Is TP53 dysfunction required for BRCA1-associated carcinogenesis?
Authors: Schuyer, M Berns, EMJJ
Citation: M. Schuyer et Emjj. Berns, Is TP53 dysfunction required for BRCA1-associated carcinogenesis?, MOL C ENDOC, 155(1-2), 1999, pp. 143-152
Genetic alterations in ovarian borderline tumours and ovarian carcinomas
Authors: Schuyer, M Henzen-Logmans, SC van der Burg, MEL Fieret, JH Derksen, C Look, MP Meijer-van Gelder, ME Klijn, JGM Foekens, JA Berns, EMJJ
Citation: M. Schuyer et al., Genetic alterations in ovarian borderline tumours and ovarian carcinomas, EUR J OB GY, 82(2), 1999, pp. 147-150
Altered expression of p53 and its regulated proteins in phyllodes tumours of the breast
Authors: Kuenen-Boumeester, V Henzen-Logmans, SC Timmermans, MM Van Staveren, IL Van Geel, A Peeterse, HJ Bonnema, J Berns, EMJJ
Citation: V. Kuenen-boumeester et al., Altered expression of p53 and its regulated proteins in phyllodes tumours of the breast, J PATHOLOGY, 189(2), 1999, pp. 169-175
Prognostic and predictive factors in breast cancer
Authors: Klijn, JGM Berns, EMJJ Foekens, JA
Citation: Jgm. Klijn et al., Prognostic and predictive factors in breast cancer, CONT ENDOC, 11, 1999, pp. 205-220
Risultati: 1-10 |